Research programme: aminopyrazole based therapeutics - Takeda/DNDi

Drug Profile

Research programme: aminopyrazole based therapeutics - Takeda/DNDi

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; Takeda
  • Class Pyrazoles; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Visceral leishmaniasis

Most Recent Events

  • 05 Apr 2018 Takeda and Drugs for Neglected Diseases initiative agree to co-develop aminopyrazoles in Japan and Switzerland for Visceral leishmaniasis
  • 27 Jul 2015 Preclinical trials in Visceral leishmaniasis in Japan (unspecified route)
  • 27 Jul 2015 Preclinical trials in Visceral leishmaniasis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top